<DOC>
	<DOCNO>NCT02950870</DOCNO>
	<brief_summary>The purpose study determinate AMH level antiviral therapy Ombitasvir-Paritaprevir-Ritonavir Dasabuvir comparison age-matched HCV-positive woman undergo antiviral treatment .</brief_summary>
	<brief_title>Efficacy Study Evaluate Effect New Antiviral Drugs HCV Infection .</brief_title>
	<detailed_description>The study interventional , control randomize ( block 2:1 case : control ) open label .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Female 18 35 year age time Screening Childbearing potential sexually active male partner ( ) currently use least one effective method birth control time screen two effective method birth control receive study drug , start Study Day 1 7 month stop study drug . Females must negative result pregnancy test Chronic HCVinfection prior study enrollment Screening laboratory result indicate HCV GT 1b GT 1a GT 4 infection . Must able voluntarily sign date inform consent form Liver biopsy within 24 month prior screen demonstrate Metavir score 2 less Ishak score 3 less Screening FibroScan® result ≤ 9.6 kPa ; Women pregnant breastfeed Positive test result HBsAg HIV Ab Recent history drug alcohol HCV genotype perform screen indicate 1 subtype coinfection genotype . Use medication contraindicate Use know strong inducer cytochrome P450 3A ( CYP3A ) strong inducer cytochrome P450 2C8 ( CYP2C8 ) strong inhibitor CYP2C8 History solid organ transplant . Confirmed presence hepatocellular carcinoma Current use investigational commercially available antiHCV agent Screening laboratory analysis show follow abnormal laboratory result</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>